Abaloparatide (Tymlos ®)
Abaloparatide is approved by the FDA for the treatment of osteoporosis, and is specifically indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Abaloparatide is supplied as an injection for subcutaneous injection. Cumulative use of abaloparatide and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended. Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.
Adverse effects associated with the use of abaloparatide may include, but are not limited to, the following: hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo.
Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma, a malignant bone tumor, in male and female rats. It is unknown whether abaloparatide will cause osteosarcoma in humans. Use of abaloparatide is not recommended in patients at increased risk for osteosarcoma.
Cumulative use of abaloparatide and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.
Mechanism of Action
Abaloparatide is a human parathyroid hormone related peptide [PTHrP(1-34)] analog, which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral site.
Last Reviewed 03/07/2018